Dikkat eksikliği hiperaktivite bozukluğu olan bir ergende modifiye salımlı metilfenidat kaynaklı Raynaud fenomeni

Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder

___

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC, American Psychiatric Association. 2013.
2. Golmirzaei J, Mahboobi H, Yazdanparast M, Mushtaq G, A Kamal M, Hamzei E. Psychopharmacology of attention-deficit hyperactivity disorder: effects and side effects. Curr Pharm Des. 2016;22:590-4.
3. Cantu C, Arauz A, Murillo Bonilla LM, López M, Barinagarrementeria F. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke. 2003;34:1667–72.
4. Jefferson HJ, Jayne DR Peripheral vasculopathy and nephropathy in association with phentermine. Nephrol Dial Transplant. 1999;14:1761–3.
5. Kokkinos J, Levine SR. Possible association of ischemic stroke with phenteramine. Stroke. 1993;24:310–3.
6. Karayagmurlu A, Coskun M. Successful management of methylphenidate or atomoxetine-related priapism during attention-deficit hyperactivity disorder treatment. J Clin Psychopharmacol. 2020;40:314-5.
7. Prete M, Fatone MC, Favoino E, Perosa F. Raynaud’s phenomenon: From molecular pathogenesis to therapy. Autoimmun Rev. 2014;13:655–67.
8. Yu ZJ, Parker-Kotler C, Tran K, Weller RA, Weller EB. Peripheral vasculopathy associated with psychostimulant treatment in children with attention- deficit/hyperactivity disorder. Curr Psychiatry Rep. 2010;12:111–5.
9. Ferahkaya H, Akça ÖF. Methylphenidate-induced raynaud’s phenomenon in two cases with attention- deficit/hyperactivity disorder. Journal of Contemporary Medicine. 2021;11:423-4.
10. Syed RH, Moore TL. Methylphenidate and dextroamphetamine-induced peripheral vasculopathy. J Clin Rheumatol. 2008;14:30–3.
11. Bayram Ö, Hergüner S. OROS-methylphenidate- induced Raynaud’s phenomenon: A dose-related side effect. J Child Adolesc Psychopharmacol. 2015;25:521–2.
12. Meridor K, Levy Y. Systemic sclerosis induced by CNS stimulants for ADHD: a case series and review of the literature. Autoimmun Rev. 2020;19:102439.
13. Khouri C, Blaise S, Carpentier P, Villier C, Cracowski JL, Roustit M. Drug-induced Raynaud’s phenomenon: beyond β-adrenoceptor blockers. Br J Clin Pharmacol. 2016;82:6–16.
14. Faraone SV. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–70.
15. Goldman W, Seltzer R, Reuman P: Association between treatment with central nervous system stimulants and Raynaud’s syndrome in children. Arthritis Rheum. 2008;58:563–6.
16. Monteerarat Y, Pariwatcharakul P. Methylphenidate- induced raynaud phenomenon developed after increasing methylphenidate in an adult with attention- deficit hyperactivity disorder. J Clin Psychopharmacol. 2019;39:178-9.